A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic-Clonic Seizures

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic-Clonic Seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Tonic-clonic epilepsy
  • Focus Registrational; Therapeutic Use
  • Acronyms Study 332
  • Sponsors Eisai Inc
  • Most Recent Events

    • 28 Apr 2017 Results of post hoc anlaysis (n=138) presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of a pooled analysis assessing the long-term efficacy and safety of adjunctive perampanel in patients from four phase II/III open-label extension studies (207, 307, 335 and 332), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 13 Apr 2017 According to an Eisai Inc media release, results of pooled analysis assessing long-term efficacy and safety of adjunctive perampanel from four open-label extension studies (207, 307, 335 and 332) will be presented at the American Academy of Neurology (AAN) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top